000153.SZ
Anhui Fengyuan Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.92
−2.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.8B | 3.9B | 4.3B | 4.3B | 4.0B |
| Cost of Revenue | 3.1B | 3.1B | 3.4B | 3.2B | 2.9B |
| Gross Profit | 693.6M | 708.9M | 932.5M | 1.1B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 38.1M | 48.9M | 63.1M | 77.0M | 65.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 171.0M | 170.2M | 178.6M | 197.6M | 166.8M |
| Selling & Marketing Expense | 303.4M | 307.9M | 472.3M | 584.3M | 680.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 576.7M | 592.7M | 777.0M | 922.3M | 975.4M |
| Cost and Expenses | 3.6B | 3.7B | 4.1B | 4.1B | 3.8B |
| Operating Income (EBIT) | 126.6M | 126.1M | 205.1M | 213.3M | 202.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 125.5M | 125.2M | 208.7M | 214.9M | 202.3M |
| Income Tax Expense | 31.6M | 30.4M | 51.1M | 57.6M | 51.4M |
| Bottom Line | |||||
| Net Income | 98.4M | 99.4M | 160.8M | 159.3M | 154.4M |
| Earnings from Cont. Ops | 93.9M | 94.8M | 157.7M | 157.3M | 150.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 98.4M | 99.4M | 160.8M | 159.3M | 154.4M |
| Per Share | |||||
| Basic EPS | CN¥0.21 | CN¥0.21 | CN¥0.35 | CN¥0.34 | CN¥0.49 |
| Diluted EPS | CN¥0.21 | CN¥0.21 | CN¥0.35 | CN¥0.34 | CN¥0.49 |
| Revenue Per Share | CN¥8.07 | CN¥8.30 | CN¥9.22 | CN¥9.20 | CN¥12.62 |
| Shares | |||||
| Basic Shares Outstanding | 464.9M | 464.8M | 464.7M | 464.9M | 317.2M |
| Diluted Shares Outstanding | 464.9M | 464.8M | 464.7M | 464.9M | 317.2M |
| Profitability Metrics | |||||
| EBITDA | — | 262.0M | 322.0M | 328.6M | 308.7M |
| D&A | — | 135.9M | 116.9M | 115.3M | 106.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026